Price
$8.75
Increased by +2.46%
Dollar volume (20D)
10.55 M
ADR%
9.64
Shares float
41.11 M
Shares short
5.51 M [13.41%]
Shares outstanding
50.39 M
Market cap
430.32 M
Beta
1.09
Price/earnings
N/A
20D range
7.82 11.00
50D range
5.85 11.00
200D range
5.04 13.48

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.

Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II.

It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease.

In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies.

Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States.

REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 6, 25 0.12
Increased by +109.02%
0.49
Decreased by -75.29%
Feb 25, 25 -1.01
Increased by +29.37%
-1.08
Increased by +6.86%
Nov 6, 24 -1.17
Increased by +17.02%
-1.12
Decreased by -4.46%
Aug 1, 24 -1.05
Increased by +36.75%
-1.29
Increased by +18.60%
May 8, 24 -1.33
Increased by +13.07%
-1.26
Decreased by -5.56%
Feb 27, 24 -1.43
Decreased by -3.62%
-1.27
Decreased by -12.60%
Nov 8, 23 -1.41
Increased by +19.43%
-1.52
Increased by +7.24%
Aug 2, 23 -1.66
Decreased by -5.06%
-1.38
Decreased by -20.29%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 25 89.01 M
Increased by +469.79%
6.08 M
Increased by +109.61%
Increased by +6.83%
Increased by +101.69%
Dec 31, 24 21.21 M
Decreased by -4.50%
-51.19 M
Increased by +18.61%
Decreased by -241.28%
Increased by +14.78%
Sep 30, 24 24.20 M
Decreased by -16.31%
-59.60 M
Increased by +3.67%
Decreased by -246.30%
Decreased by -15.11%
Jun 30, 24 22.30 M
Increased by +11.60%
-52.99 M
Increased by +26.47%
Decreased by -237.67%
Increased by +34.11%
Mar 31, 24 15.62 M
Decreased by -18.37%
-63.33 M
Increased by +9.46%
Decreased by -405.39%
Decreased by -10.91%
Dec 31, 23 22.21 M
Decreased by -29.13%
-62.89 M
Decreased by -4.93%
Decreased by -283.12%
Decreased by -48.07%
Sep 30, 23 28.91 M
Increased by +9.06%
-61.87 M
Increased by +22.59%
Decreased by -213.97%
Increased by +29.02%
Jun 30, 23 19.98 M
Decreased by -38.81%
-72.06 M
Decreased by -5.69%
Decreased by -360.72%
Decreased by -72.74%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY